DNAJC11

Across TCGA pan-cancer cohorts, DNAJC11 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DNAJC11 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DNAJC11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated DNAJC11 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LUAD, and HNSC are the cancer types where DNAJC11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.146	0.702	.010	9	view →
LUAD	DFS	Quartile	All	0.497	0.741	.027	4	view →
HNSC	DFS	Median	II,III,IV	0.892	0.980	.027	3	view →
GBM	DFS	Median	All	0.829	0.667	.032	1	view →
LSCC	DFS	Median	All	0.715	0.855	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DNAJC11–PDAC (OS)

Open the PDAC breakdown →